RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPAC Read more 

MapLight shares sink on mixed phase 2 schizophrenia readout Read more 

Apnimed aspires for up to $160M IPO as sleep apnea pill launch nears Read more 

Max Eldridge

Max has more than ten years in Life Sciences recruitment, He collaborates with executives to foster growth in Pharma, Biotech, CRO, TechBio, and Medical Device sectors​

Contractors

Timesheet Portal

Clients
Legal
Contact Us

Copyright © 2026 | Hlx Life Sciences

Go to Top